Suppr超能文献

累及野放疗对70岁及以上的早期非小细胞肺癌患者有效。

Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer.

作者信息

Yu Hui Ming, Liu Yun Fang, Yu Jin Ming, Liu Jie, Zhao Yuxia, Hou Ming

机构信息

Department of Oncology, Shandong University Medical School, Qilu Hospital, Jinan, PR China.

出版信息

Radiother Oncol. 2008 Apr;87(1):29-34. doi: 10.1016/j.radonc.2008.01.008. Epub 2008 Jan 30.

Abstract

BACKGROUND AND PURPOSE

Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all lung cancers, especially in patients 70 years old or more. In this study, we investigated the efficacy and safety of involved-field radiotherapy (IFRT) for patients 70 years old or more with early stage NSCLC.

PATIENTS AND METHODS

We conducted a multicenter prospective study in elderly patients with NSCLC treated with intensity-modulated radiotherapy (IMRT). From January 1999 to December 2001, 80 patients with medically inoperable or refused surgery early stage (I/II) NSCLC were eligible for toxicity and treatment response analysis. IMRT plans were designed to deliver 66.6 Gy to involved-field that included only the primary tumor and clinically enlarged lymph nodes using six equidistant coplanar 6-MV beams. Elective nodal failure (ENF) was defined as a recurrence in an initially uninvolved lymph node in the absence of local failure.

RESULTS

The objective response rate of all patients was 88.6% with a median overall survival (OS) time of 38 months and the 1-, 2- and 5-year OS rates and local progression-free survival (LPFS) rates were 65.8%, 55.7%, 25.3% and 84.8%, 59.5%, 34.2%, respectively. The medians OS time for patients with gross tumor volume (GTV) >100.8 cm3 and GTV < or =100.8 cm3 were 13 and 50 months, respectively (p=0.0001). Only 29 patients (36.7%) with ENF were identified, with a median time to treatment failure of 55 months (range, 49-61 months) after treatment. There were no treatment-related deaths or grade 4 toxicity. Grade 3 toxicities were esophagitis (1.3%), radiation pneumonitis (3.8%) and hematological effects (2.5%).

CONCLUSIONS

This study indicated that IFRT using IMRT did not cause a significant amount of failure in lymph node regions not included in the tumor volume and improved outcomes in elderly patients. Therefore, IFRT is an acceptable technique in the treatment of elderly inoperable NSCLC.

摘要

背景与目的

非小细胞肺癌(NSCLC)约占所有肺癌的80 - 85%,在70岁及以上患者中尤为常见。在本研究中,我们调查了调强放疗(IMRT)对70岁及以上早期NSCLC患者的疗效和安全性。

患者与方法

我们对接受IMRT治疗的老年NSCLC患者进行了一项多中心前瞻性研究。从1999年1月至2001年12月,80例医学上无法手术或拒绝手术的早期(I/II期)NSCLC患者符合毒性和治疗反应分析标准。IMRT计划设计为使用六束等距共面6 - MV射线向仅包括原发肿瘤和临床肿大淋巴结的靶区给予66.6 Gy剂量。选择性淋巴结失败(ENF)定义为在无局部失败的情况下,最初未受累淋巴结出现复发。

结果

所有患者的客观缓解率为88.6%,中位总生存期(OS)为38个月,1年、2年和5年OS率以及局部无进展生存期(LPFS)率分别为65.8%、55.7%、25.3%和84.8%、59.5%、34.2%。大体肿瘤体积(GTV)>100.8 cm³和GTV≤100.8 cm³患者的中位OS时间分别为13个月和50个月(p = 0.0001)。仅29例(36.7%)患者出现ENF,治疗后至治疗失败的中位时间为55个月(范围49 - 61个月)。无治疗相关死亡或4级毒性反应。3级毒性反应包括食管炎(1.3%)、放射性肺炎(3.8%)和血液学影响(2.5%)。

结论

本研究表明,使用IMRT的累及野放疗(IFRT)在肿瘤体积未包括的淋巴结区域未导致大量失败,并改善了老年患者的预后。因此,IFRT是治疗老年无法手术NSCLC的一种可接受的技术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验